Novel Bio therapeutics and Drug Delivery Systems

The demand for biotherapeutics is continuously increasing, because many biopharmaceutical drugs are reaching later stage clinical trials. Most biotherapeutic drugs are recombinant monoclonal antibodies which are widely produced in mammalian cell lines because of the need for post-translational modifications that should be alike or at least similar to those obtained in humans. Thus, there is an increase in the market for cell line development. Moreover, advancements in upstream processing technologies have led to improvement in speed and efficiency of generating robust and highly productive cell line for large scale production of protein therapeutics and has propelled the market for cell line development.

Major drugs driving growth of the overall smart drug delivery market include Angiomax, Copaxone, Forteo, Sandostatin, Velcade, Victoza,  Zoladex, Beckton Dickinson & Company (U.S.), Beckman Coulter (U.S.), Boehringer Ingelheim Group (Germany), Catalent Inc. (U.S.), CMC Biologics A/S (Denmark), Lonza Group Ltd. (Switzerland), EMD Millipore (U.S.), Partec (Sysmex Corporation) (Japan), ProBioGen AG (Germany), Selexis SA (Germany), Sigma-Aldrich Co. LLC. (U.S.), Sony Biotechnology Inc. (U.S.), and Thermo Fisher Scientific Inc. (U.S.)

According to a New Market Research “Bio therapeutics as Novel Technique in Drug Delivery  - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2022”, the Bio therapeutics as Novel Technique in Drug Delivery  was valued at US$56.03 mn in 2015 and is anticipated to expand at a CAGR of 7.5% from 2015 to 2022 to reach US$99.84 mn by 2022.

 

Bringing a drug candidate to successful commercialization is always a challenging task, but it is one that has been made more difficult through the increase of poorly water-soluble drugs. In the development of a commercial drug product, the formulator must consider various perspectives. The bioavailability of the active drug substance is often the major hurdle to overcome. In the past it has been common to add viscosity-enhancing agents or mucoadhesive polymers into formulations to improve ocular bioavailability. In addition to these conventional approaches, non-conventional technologies such as nanotechnology, microspheres and prodrugs could be considered to optimize the product.

  • Biotherapeutics formulations
  • Biotherapeutics Technique in Drug Delivery
  • Nonclinical toxicology testing strategies
  • Stability of Pharmaceutical products
  • Advances in computational modeling for bioavailability
  • Recent Developments in QBD
  • Services for the Pharmaceutical Industry
  • CRO – Contract Research Organisations

Related Conference of Novel Bio therapeutics and Drug Delivery Systems

Novel Bio therapeutics and Drug Delivery Systems Conference Speakers